CX3CR1 and pulmonary arterial hypertension: An increase in CX3CR1 and its ligand fractalkine has previously been reported in PAH patients [36], although that study primarily found it in CD4+ cells, whereas we did not have positivity in CD4+ cells in either controls or PAH.